c-Jun N-Terminal Kinases in Alzheimer's Disease: A Possible Target for the Modulation of the Earliest Alterations

J Alzheimers Dis. 2021;82(s1):S127-S139. doi: 10.3233/JAD-201053.

Abstract

Given the highly multifactorial origin of Alzheimer's disease (AD) neuropathology, disentangling and orderly knowing mechanisms involved in sporadic onset are arduous. Nevertheless, when the elements involved are dissected into smaller pieces, the task becomes more accessible. This review aimed to describe the link between c-Jun N-terminal Kinases (JNKs), master regulators of many cellular functions, and the early alterations of AD: synaptic loss and dysregulation of neuronal transport. Both processes have a role in the posterior cognitive decline observed in AD. The manuscript focuses on the molecular mechanisms of glutamatergic, GABA, and cholinergic synapses altered by the presence of amyloid-β aggregates and hyperphosphorylated tau, as well as on several consequences of the disruption of cellular processes linked to neuronal transport that is controlled by the JNK-JIP (c-jun NH2-terminal kinase (JNK)-interacting proteins (JIPs) complex, including the transport of AβPP or autophagosomes.

Keywords: Alzheimer’s disease; JNK; amyloid-β; axonal transport; hyperphosphorylated tau; synapse loss.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / pathology
  • Animals
  • Brain-Derived Neurotrophic Factor / metabolism
  • Drug Delivery Systems / methods
  • Glutamic Acid / metabolism
  • Humans
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • JNK Mitogen-Activated Protein Kinases / metabolism*
  • Nerve Growth Factor / metabolism
  • Neurons / drug effects
  • Neurons / metabolism*
  • Neurons / pathology
  • Protein Kinase Inhibitors / administration & dosage
  • Synapses / drug effects
  • Synapses / metabolism*
  • Synapses / pathology
  • gamma-Aminobutyric Acid / metabolism

Substances

  • Brain-Derived Neurotrophic Factor
  • NGF protein, human
  • Protein Kinase Inhibitors
  • Glutamic Acid
  • gamma-Aminobutyric Acid
  • BDNF protein, human
  • Nerve Growth Factor
  • JNK Mitogen-Activated Protein Kinases